Patent ID: 8735445

Claim:
A method for promoting or stimulating pigmentation of the skin and/or skin appendages and/or limiting depigmentation and/or whitening of the skin and/or skin appendages, comprising administering to a mammalian organism in need of such treatment, a thus effective amount of at least one inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) of formula (I), or a salt thereof: in which: Hy is a heterocycle having 4, 5, 6 or 7 atoms, optionally comprising at least one carbonyl function and/or one thiocarbonyl function, said heterocycle being optionally substituted with at least one substituent selected from the group consisting of a halogen, the groups OR, SR, NRR′, COR, CSR, NRCONR′R″, C(═NR)R′, C(═NR)NR′R″, NRC(═NR′)NR″R′″, OCOR, COSR, SCOR, CSNRR′, NRCSR′, NRCSNR′R″, COOR, CONRR′, CF 3 , CN, NRCOR′, SO 2 R′, SO 2 NRR′ or NRSO 2 R′, saturated or unsaturated, linear or branched C 1 -C 20 alkyl radicals, and saturated or unsaturated rings having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the alkyl radicals and the rings may be substituted, wherein R, R′, R″ and R′″, which may be identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted; G is S, R 1 , R 2 and R 3 represent, independently of one another, a hydrogen, a halogen, a group OR 0 , SR 0 , NR 0 R′ 0 , COR 0 , CSR 0 , NR 0 CONR′ 0 R″ 0 , C(═NR 0 )R′ 0 , C(═NR 0 )NR′ 0 R″ 0 , NR 0 C(═NR′ 0 )NR″ 0 R″′ 0 , OCOR 0 , COSR 0 , SCOR 0 , CSNR 0 R′ 0 , NR 0 CSR′ 0 , NR 0 CSNR′ 0 R′ 0 , COOR 0 , CONR 0 R′ 0 , CF 3 , NO 2 , CN, NR 0 COR′ 0 , SO 2 R′ 0 , SO 2 NR 0 R′ 0 or NR 0 SO 2 R′ 0 , a saturated or unsaturated, linear or branched C 1 -C 20 alkyl radical, or at least one saturated or unsaturated ring having 4 to 7 atoms, optionally containing at least one hetero atom, with the proviso that the rings may be separated or attached, also with the proviso that the alkyl radicals and the rings may be substituted, wherein R 0 , R′ 0 , R″ 0 and R′″ 0 , which may identical or different, are each a hydrogen, or a linear or branched C 1 -C 20 alkyl radical or an aryl radical, that is optionally substituted, wherein said inhibitor also has prostaglandin synthase-inhibiting activity, and the ratio of the 15-PGDH-inhibiting activity of said at least one inhibitor of 15-PGDH to the prostaglandin synthase-inhibiting activity thereof is greater than 1.